Search Results for "Tiazac"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Tiazac. Results 1 to 5 of 5 total matches.
See also: diltiazem
Safety of Calcium-Channel Blockers
The Medical Letter on Drugs and Therapeutics • Feb 14, 1997 (Issue 994)
− extended-release− Cardizem CD ✔✔✔
Dilacor XR
Cardizem SR; Tiamate; Tiazac ✔
Verapamil − extended-release ...
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Nisoldipine-A New Calcium-Channel Blocker for Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
in 1 dose 31.32
Dilacor XR 120-480 mg in 1 dose 27.79
Tiazac 120-540 mg in 1 dose 23.56
Verapamil ...
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Mibefradil--A New Calcium-Channel Blocker
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997 (Issue 1013)
Marion Roussel) 180 mg once daily 40.74
Dilacor XR (Watson) 35.72
Tiazac (Forest) 120-240 mg once daily ...
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
(Valeant)
Matzim LA (Teva)
generic (extended-release)
Taztia XT (Actavis)
Tiadylt ER (Zydus)
Tiazac ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
)
Cardizem LA (Bausch)
Cartia XT (Teva)
Taztia XT (Teva)
Tiazac (Bausch)
120, 180, 240, 300, 360 mg ER ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction